Table 4. Sensitivity analysis in non-muscle invasive bladder tumor.

	No. of included articles	No. of cases	Pooled HR (95% CI)	I2	Chi2 (p value)
Recurrence-free survival	5*	362	2.32 (1.53–3.52)	0%	3.52 (0.48)
Progression-free survival	5**	916	2.15 (1.62–2.86)	0%	3.27 (0.51)
Cancer-specific survival	4†	506	2.01 (1.32–3.06)	7%	3.21 (0.36)
Overall survival	2‡	363	1.53 (1.02–2.29)	0%	0.13 (0.72)

HR: hazard ratio, CI: confidence interval.

^*References: [53], [56], [58], [59], [61].

^**References: [55,56,59,60 (Denmark cohort),60 (validation cohort)].

^†References: [55,56,59,60 (Denmark cohort)].

^‡References: [58,60 (Denmark cohort)].